scholarly journals Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample

Diabetologia ◽  
2021 ◽  
Author(s):  
Naiara G. Bediaga ◽  
Connie S. N. Li-Wai-Suen ◽  
Michael J. Haller ◽  
Stephen E. Gitelman ◽  
Carmella Evans-Molina ◽  
...  

Abstract Aims/hypothesis Accurate prediction of disease progression in individuals with pre-symptomatic type 1 diabetes has potential to prevent ketoacidosis and accelerate development of disease-modifying therapies. Current tools for predicting risk require multiple blood samples taken during an OGTT. Our aim was to develop and validate a simpler tool based on a single blood draw. Methods Models to predict disease progression using a single OGTT time point (0, 30, 60, 90 or 120 min) were developed using TrialNet data collected from relatives with type 1 diabetes and validated in independent populations at high genetic risk of type 1 diabetes (TrialNet, Diabetes Prevention Trial–Type 1, The Environmental Determinants of Diabetes in the Young [1]) and in a general population of Bavarian children who participated in Fr1da. Results Cox proportional hazards models combining plasma glucose, C-peptide, sex, age, BMI, HbA1c and insulinoma antigen-2 autoantibody status predicted disease progression in all populations. In TrialNet, the AUC for receiver operating characteristic curves for models named M60, M90 and M120, based on sampling at 60, 90 and 120 min, was 0.760, 0.761 and 0.745, respectively. These were not significantly different from the AUC of 0.760 for the gold standard Diabetes Prevention Trial Risk Score, which requires five OGTT blood samples. In TEDDY, where only 120 min blood sampling had been performed, the M120 AUC was 0.865. In Fr1da, the M120 AUC of 0.742 was significantly greater than the M60 AUC of 0.615. Conclusions/interpretation Prediction models based on a single OGTT blood draw accurately predict disease progression from stage 1 or 2 to stage 3 type 1 diabetes. The operational simplicity of M120, its validity across different at-risk populations and the requirement for 120 min sampling to stage type 1 diabetes suggest M120 could be readily applied to decrease the cost and complexity of risk stratification. Graphical abstract

Diabetes Care ◽  
2006 ◽  
Vol 29 (3) ◽  
pp. 643-649 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Palmer ◽  
C. J. Greenbaum ◽  
J. Mahon ◽  
C. Cowie ◽  
...  

2021 ◽  
Author(s):  
Michael G Voss ◽  
David D Cuthbertson ◽  
Mario M Cleves ◽  
Ping Xu ◽  
Carmella Evans-Molina ◽  
...  

<b>Objective:</b> To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody positive (Ab+) relatives of people with type 1 diabetes. <p><b>Methods:</b> We examined 2-hour OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (Mean±SD age: 13.84±9.53 years; BMI-Z-Score: 0.33±1.07; 56.1% male) and 3,720 PTP participants (age: 16.01±12.33 Years, BMI-Z-Score 0.66±1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-Score, HOMA-IR and peak Glucose/C-peptide levels, respectively) were performed. </p> <p><b>Results:</b> In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose >30 min and time to peak C-peptide >60 min (p<0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: X<sup>2 </sup>= 25.76 vs. X<sup>2</sup> = 8.62 and PTP: X<sup>2 </sup>= 149.19 vs. X<sup>2</sup> = 79.98; all p<0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time.</p> <p><b>Conclusions: </b>In two independent at risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression. </p>


Diabetes Care ◽  
2008 ◽  
Vol 31 (11) ◽  
pp. 2188-2192 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Palmer ◽  
L. Rafkin-Mervis ◽  
J. P. Krischer ◽  
D. Cuthbertson ◽  
...  

2009 ◽  
Vol 10 (3) ◽  
pp. 177-183 ◽  
Author(s):  
Suzanne Bennett Johnson ◽  
Amy E Baughcum ◽  
Lisa E Rafkin-Mervis ◽  
Desmond A Schatz ◽  

Diabetes Care ◽  
2007 ◽  
Vol 31 (3) ◽  
pp. 528-533 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Krischer ◽  
J. P. Palmer ◽  
J. Mahon ◽  
C. Cowie ◽  
...  

Diabetes Care ◽  
2014 ◽  
Vol 37 (4) ◽  
pp. 979-984 ◽  
Author(s):  
Jay M. Sosenko ◽  
Jay S. Skyler ◽  
Jeffrey Mahon ◽  
Jeffrey P. Krischer ◽  
Carla J. Greenbaum ◽  
...  

Diabetes Care ◽  
2012 ◽  
Vol 35 (7) ◽  
pp. 1552-1555 ◽  
Author(s):  
J. M. Sosenko ◽  
J. S. Skyler ◽  
J. Mahon ◽  
J. P. Krischer ◽  
C. A. Beam ◽  
...  

2013 ◽  
Vol 11 (2) ◽  
pp. 150-158 ◽  
Author(s):  
Margaret Franciscus ◽  
Anita Nucci ◽  
Brenda Bradley ◽  
Heli Suomalainen ◽  
Ellen Greenberg ◽  
...  

Diabetes Care ◽  
2009 ◽  
Vol 32 (12) ◽  
pp. 2269-2274 ◽  
Author(s):  
T. Orban ◽  
J. M. Sosenko ◽  
D. Cuthbertson ◽  
J. P. Krischer ◽  
J. S. Skyler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document